15 December 2002
Perioperative Use of Recombinant Activated Factor VII in Liver Transplantation
L Jureczko, M Kołacz, J Trzebicki, G Szyszko, M Pacholczyk, B Łągiewska, A Chmura, W Rowiński, E Mayzner-ZawadzkaAnn Transplant 2003; 8(4): 40-42 :: ID: 7547
Abstract
Recombinant activated factor VII (rFVIIa, NovoSeven, Novo Nordisk A/S, Denmark) is a treatment used to prevent and arrest intra- and
postoperative bleeds in patients with haemophilia A or B complicated by circulating anticoagulants (inhibitors of FVIII and FIX).
Patients who qualify for liver transplantation may have varying degrees of coagulation impairment, which may adversely impact elective anaesthetic and surgical procedures and elevate the risk of intraoperative bleeds, which require massive blood transfusions and worsen prognosis. Recently, reports have been published on the use of rFVIIa prior to surgical procedures, which are likely to cause severe blood loss as well as for so-called emergency therapy of coagulation disorders during liver transplantation.
In Press
Original article
The Anatomical Landscape of Living Donor Livers: A 101-Case Retrospective Single-Center Study in Indonesia ...Ann Transplant In Press; DOI: 10.12659/AOT.952031
Original article
Decreased Ventilation Duration and ICU Stay Associated With Early Percutaneous Dilatational Tracheostomy Af...Ann Transplant In Press; DOI: 10.12659/AOT.953143
Original article
Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients With Posttransplant Lymphoproliferati...Ann Transplant In Press; DOI: 10.12659/AOT.952021
Original article
Common Versus External Iliac Arterial Anastomosis in Kidney Transplantation: A Bicentric Retrospective Anal...Ann Transplant In Press; DOI: 10.12659/AOT.953269
Most Viewed Current Articles
24 Aug 2021 : Review article 20,864
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 17,029
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
05 Apr 2022 : Original article 16,094
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 16,067
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988